Human Cxcl15 (C-X-C motif chemokine 15) ELISA Kit

Metastasis is the most devastating aspect of cancer, however we know very little about the mechanisms of local invasion, the earliest step of metastasis. During tumor growth CD11b(+)Gr1(+) cells, known also as MDSCs, have been shown to promote tumor progression by a wide spectrum of effects that suppress the anti-tumor immune response. In addition to immunosuppression, CD11b(+)Gr1(+) cells promote metastasis by mechanisms that are currently unknown. CD11b(+)Gr1(+) cells localize near fibroblasts, which remodel the ECM and leave tracks for collective cell migration of carcinoma cells. In this study we discovered that CD11b(+)Gr1(+) cells promote invasion of mammary carcinoma cells by increasing fibroblast migration. This effect was directed by secreted factors derived from CD11b(+)Gr1(+) cells. We have identified several CD11b(+)Gr1(+) cell secreted proteins that activate fibroblast migration, including CXCL11, CXCL15, FGF2, IGF-I, IL1Ra, Resistin, and Shh. The combination of CXCL11 and FGF2 had the strongest effect on fibroblast migration that is associated with Akt1 and ERK1/2 phosphorylation. Analysis of subsets of CD11b(+)Gr1(+) cells identified that CD11b(+)Ly6C(high)Ly6G(low) cells increase fibroblast migration more than other myeloid cell populations. Additionally, tumor-derived CD11b(+)Gr1(+) cells promote fibroblast migration more than splenic CD11b(+)Gr1(+) cells of tumor-bearing mice. While TGF beta signaling in fibroblasts does not regulate their migration toward CD11b(+)Gr1(+) cells, however deletion of TGF beta receptor II on CD11b(+)Gr1(+) cells downregulates CXCL11, Shh, IGF1 and FGF2 resulting in reduced fibroblast migration. These studies show that TGF beta signaling in CD11b(+)Gr1(+) cells promotes fibroblast directed carcinoma invasion and suggests that perivascular CD11b(+)Ly6C(high)Ly6G(low) cells may be the stimulus for localized invasion leading to metastasis.

Lipopolysaccharide (LPS) is an endotoxin involved in a number of acute and chronic inflammatory syndromes. Although LPS-induced signalling has been extensively studied, there are still mysteries remaining to be revealed. In the current study, we used high-throughput phosphoproteomics to profile LPS-initiated signalling and aimed to find novel mediators. A total of 448 phosphoproteins with 765 phosphorylation sites were identified, and we further validated that the phosphorylation of MARK2 on T208 was important for the regulation on LPS-induced CXCL15 (human IL-8 homolog), IL-1 beta, IL-6 and TNF-alpha release, in which LKB1 had a significant contribution. In summary, induction of cytokines by LPS in mouse macrophage is regulated by LKB1-MARK2 signals. Our study provides new clues for further exploring the underlying mechanisms of LPS-induced diseases, and new therapeutic approaches concerning bacterial infection may be derived from these findings.